Tech Company Financing Transactions
Oncgnostics Funding Round
Oncgnostics, based in Jena, raised investment capital from Grande Bio-tech Co.
Transaction Overview
Company Name
Announced On
9/11/2023
Transaction Type
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to expand the distribution of its tests developed in the ASEAN countries.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Löbstedter Str. 41
Jena, 07749
DE
Jena, 07749
DE
Phone
Website
Email Address
Overview
As a biotechnology company, we at oncgnostics GmbH have been working on the diagnosis of cancer on a molecular biological basis since 2012. Our cancer tests are used in early cancer detection and diagnosis. Our first product, GynTect®, was developed with the aim of improving the early detection of cervical cancer. The molecular biological test for cervical cancer has been on the market since 2015 and exemplifies the technology we specialise in as a biotech company: Highly informative biomarkers patented by oncgnostics GmbH form the core of the company. Experienced scientists work together on innovative cancer diagnostics of the future. As a spin-off of the University Women's Hospital Jena, oncgnostics GmbH with its research and development team works with international partners on various pipeline projects.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Alfred Hansel
Co-Founder
Kerstin Brox
Co-Founder
Martina Schmitz
Browse more venture capital transactions:
Prev: 9/11/2023: Hadrius venture capital transaction
Next: 9/11/2023: BlueWave venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs